Esperion Therapeutics, Inc.
(NASDAQ : ESPR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading ESPR News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.04%68.550.9%$505.54m
AMGNAmgen Inc.
0.37%163.321.1%$461.64m
BIIBBiogen Inc.
-1.94%271.211.2%$423.43m
CELGCelgene Corporation
0.07%124.051.2%$383.45m
REGNRegeneron Pharmaceuticals, Inc.
5.97%388.492.7%$332.95m
ALXNAlexion Pharmaceuticals, Inc.
0.69%127.781.9%$250.96m
INCYIncyte Corporation
0.09%124.282.6%$247.36m
VRTXVertex Pharmaceuticals Incorporated
0.75%118.301.9%$235.75m
ILMNIllumina, Inc.
0.61%184.863.5%$200.54m
TSROTESARO, Inc.
0.67%147.5914.7%$130.72m
NBIXNeurocrine Biosciences, Inc.
-0.36%53.405.3%$114.24m
BMRNBioMarin Pharmaceutical Inc.
-0.40%95.884.5%$113.09m
KITEKite Pharma, Inc.
-0.68%82.0816.6%$94.29m
AAgilent Technologies, Inc.
-0.70%55.041.5%$93.33m
SRPTSarepta Therapeutics, Inc.
4.44%36.2619.8%$82.73m

Company Profile

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. It is in business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The company was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.